FDA Pilots One-Day Inspectional Assessments to Expand Oversight

The U.S. Food and Drug Administration (FDA) is piloting one-day inspectional assessments to make oversight more targeted and efficient. Launched in April 2026, the initiative introduces shorter, focused screening visits alongside standard inspections. The FDA says the approach is intended to broaden surveillance coverage while maintaining regulatory rigour.

The FDA describes the one-day assessments as a complement to existing inspections rather than a replacement. Investigators will still be able to expand the scope or duration of an assessment if warranted, and some visits have already extended beyond a single day when significant observations were identified.

The agency also emphasises that the pilot does not change enforcement policy and is not intended for higher-risk or more complex facilities, which continue to require more comprehensive inspectional coverage. The FDA notes that, for lower-risk establishments, this model may provide timely feedback while minimising operational disruption.

FDA leadership has positioned the pilot as a way to focus time and resources where they are most needed and to improve overall effectiveness.

As of late April 2026, the FDA reported completing approximately 46 one-day assessments. Most confirmed compliance and resulted in "No Action Indicated (NAI)" outcomes.
The pilot will continue through fiscal year 2026, with evaluation metrics under development, including inspection duration, escalation rates, and the usefulness of findings for risk-based decision-making.

What this means for regulated organisations

Organisations in FDA-regulated sectors may see an increase in shorter, focused screening visits, particularly where risk-based criteria suggest a lower-risk profile, while still needing to be prepared for escalation if observations warrant it.